Antisense Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATHJF research report →
Price Chart
About the company
Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory conditions, such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma.
- CEO
- James Garner MBA
- IPO
- 2009
- HQ
- Toorak, VIC, AU
Get TickerSpark's AI analysis on ATHJF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $2.97M+87.9%
- Gross Profit
- $2.91M+95.7%
- Op Income
- $-11,832,514
- Net Income
- $-11,919,223-4.7%
- EPS
- $-0.01+20.6%
- OCF Growth
- -24.1%
- FCF Growth
- -23.7%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 0.87
- RSI (14)
- 90
- Avg Volume
- 0
No earnings-call transcripts are available for ATHJF yet.
- Free Float
- 39.0%
- Shares Outstanding
- 1.64B
- Float Shares
- 637.49M
Our ATHJF coverage
Recent articles, reports, and earnings notes.
No research on ATHJF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATHJF report →